Sepsis Pathophysiology, Chronic Critical Illness, and Persistent Inflammation-Immunosuppression and Catabolism Syndrome
暂无分享,去创建一个
L. Moldawer | P. Efron | S. Brakenridge | Lori F. Gentile | F. Moore | A. Mohr | B. Mathias | J. Mira | Brittany J. Mathias
[1] F. Brunkhorst,et al. Sepsis-3 , 2017, Der Internist.
[2] B. Brumback,et al. Human Myeloid-derived Suppressor Cells are Associated With Chronic Immune Suppression After Severe Sepsis/Septic Shock , 2017, Annals of surgery.
[3] R. Bellomo,et al. Timing of onset and burden of persistent critical illness in Australia and New Zealand: a retrospective, population-based, observational study. , 2016, The Lancet. Respiratory medicine.
[4] Tezcan Ozrazgat-Baslanti,et al. The Pattern of Longitudinal Change in Serum Creatinine and 90-Day Mortality After Major Surgery , 2016, Annals of surgery.
[5] R. Bellomo,et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.
[6] T. Rea,et al. Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.
[7] P. Pickkers,et al. Danger in the Intensive Care Unit: Damps in Critically Ill Patients , 2016, Shock.
[8] C. Georgescu,et al. Epidemiology of severe sepsis: 2008-2012. , 2016, Journal of critical care.
[9] L. Fabbri,et al. Chronic critical illness: the price of survival , 2015, European Journal of Clinical Investigation.
[10] T. Kielian,et al. Interleukin‐10 production by myeloid‐derived suppressor cells contributes to bacterial persistence during Staphylococcus aureus orthopedic biofilm infection , 2015, Journal of leukocyte biology.
[11] P. Parizel,et al. The course of diaphragm atrophy in ventilated patients assessed with ultrasound: a longitudinal cohort study , 2015, Critical Care.
[12] Sun-Mee Lee,et al. DAMPs activating innate immune responses in sepsis , 2015, Ageing Research Reviews.
[13] Y. Meirow,et al. Paving the Road to Tumor Development and Spreading: Myeloid-Derived Suppressor Cells are Ruling the Fate , 2015, Front. Immunol..
[14] R. Dellinger,et al. Foreword. The Future of Sepsis Performance Improvement. , 2015, Critical care medicine.
[15] Yan Yang,et al. Diagnostic and prognostic value of myeloid-related protein complex 8/14 for sepsis. , 2015, The American journal of emergency medicine.
[16] W. Garrett,et al. CCL2 Promotes Colorectal Carcinogenesis by Enhancing Polymorphonuclear Myeloid-Derived Suppressor Cell Population and Function , 2015, Cell reports.
[17] A. S. Colombo,et al. Physical activity, muscle strength, and exercise capacity 3 months after severe sepsis and septic shock , 2015, Intensive Care Medicine.
[18] Cheng Cheng Tan,et al. The Surviving Sepsis Campaign bundles and outcome: results from the International Multicentre Prevalence Study on Sepsis (the IMPreSS study) , 2015, Intensive Care Medicine.
[19] Xue-guang Zhang,et al. Circulating CD14+HLA-DR−/low myeloid-derived suppressor cell is an indicator of poor prognosis in patients with ESCC , 2015, Tumor Biology.
[20] F. Moore,et al. Persistent inflammatory, immunosuppressed, catabolic syndrome (PICS): A new phenotype of multiple organ failure. , 2015, Journal of advanced nutritional and human metabolism.
[21] R. Hotchkiss,et al. Interleukin-7 and Anti–Programmed Cell Death 1 Antibody Have Differing Effects to Reverse Sepsis-Induced Immunosuppression , 2015, Shock.
[22] D. Annane,et al. Critical care evidence--new directions. , 2015, JAMA.
[23] D. Angus,et al. The Epidemiology of Chronic Critical Illness in the United States* , 2015, Critical care medicine.
[24] P. Evans,et al. Long Term Health-Related Quality of Life in Survivors of Sepsis in South West Wales: An Epidemiological Study , 2014, PloS one.
[25] Chen Zhang,et al. Myeloid-Derived Suppressor Cells Impair Alveolar Macrophages through PD-1 Receptor Ligation during Pneumocystis Pneumonia , 2014, Infection and Immunity.
[26] L. Rydén,et al. A high frequency of MDSCs in sepsis patients, with the granulocytic subtype dominating in gram‐positive cases , 2014, Journal of leukocyte biology.
[27] E. Benjamin,et al. Long-term outcomes following development of new-onset atrial fibrillation during sepsis. , 2014, Chest.
[28] E. Golanov,et al. Brain Region-Specific Alterations in the Gene Expression of Cytokines, Immune Cell Markers and Cholinergic System Components during Peripheral Endotoxin-Induced Inflammation , 2014, Molecular medicine.
[29] S. Lemeshow,et al. Surviving Sepsis Campaign: association between performance metrics and outcomes in a 7.5-year study , 2014, Intensive Care Medicine.
[30] T. Yen,et al. IL-6-stimulated CD11b+CD14+HLA-DR− myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus , 2014, Oncotarget.
[31] P. Fayers,et al. Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a classification model--a study based on data from an international multicentre project (EPCRC-CSA). , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[32] R. Hotchkiss,et al. Parallels between cancer and infectious disease. , 2014, New England Journal of Medicine.
[33] Jinxiang Chen,et al. The effect of immune microenvironment on the progression and prognosis of colorectal cancer , 2014, Medical Oncology.
[34] Qiang Xu,et al. Axitinib augments antitumor activity in renal cell carcinoma via STAT3-dependent reversal of myeloid-derived suppressor cell accumulation. , 2014, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[35] L. Moldawer,et al. Novel Role for Tumor-Induced Expansion of Myeloid-Derived Cells in Cancer Cachexia , 2014, The Journal of Immunology.
[36] M. Heneka,et al. Long-term cerebral consequences of sepsis , 2014, The Lancet Neurology.
[37] Minho Chae,et al. Serum amyloid A3 exacerbates cancer by enhancing the suppressive capacity of myeloid‐derived suppressor cells via TLR2‐dependent STAT3 activation , 2014, European journal of immunology.
[38] Amber J. Giles,et al. Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy , 2014, Science Translational Medicine.
[39] S. Reis,et al. Risk of cardiovascular events in survivors of severe sepsis. , 2014, American journal of respiratory and critical care medicine.
[40] Markus G. Manz,et al. Emergency granulopoiesis , 2014, Nature Reviews Immunology.
[41] J. Marshall. Why have clinical trials in sepsis failed? , 2014, Trends in molecular medicine.
[42] K. Asehnoune,et al. Prevalence and impact of frailty on mortality in elderly ICU patients: a prospective, multicenter, observational study , 2014, Intensive Care Medicine.
[43] S. Bagshaw,et al. Association between frailty and short- and long-term outcomes among critically ill patients: a multicentre prospective cohort study , 2014, Canadian Medical Association Journal.
[44] D. Angus,et al. Epidemiology of severe sepsis , 2013, Virulence.
[45] N. Miyagawa,et al. Plasma mitochondrial DNA levels in patients with trauma and severe sepsis: time course and the association with clinical status. , 2013, Journal of critical care.
[46] M. Kelz,et al. Orexinergic Activity Modulates Altered Vital Signs and Pituitary Hormone Secretion in Experimental Sepsis , 2013, Critical care medicine.
[47] J. Talmadge,et al. History of myeloid-derived suppressor cells , 2013, Nature Reviews Cancer.
[48] Eileen Bulger,et al. Skeletal muscle predicts ventilator-free days, ICU-free days, and mortality in elderly ICU patients , 2013, Critical Care.
[49] S. Powers,et al. Ventilator-induced diaphragm dysfunction: cause and effect. , 2013, American journal of physiology. Regulatory, integrative and comparative physiology.
[50] A. Bihorac,et al. Acute kidney injury is surprisingly common and a powerful predictor of mortality in surgical sepsis , 2013, The journal of trauma and acute care surgery.
[51] B. Zhang,et al. Increased CD14+HLA-DR-/low myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients , 2013, Cancer Immunology, Immunotherapy.
[52] R. Hotchkiss,et al. Blockade ofthe negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis , 2013, Critical Care.
[53] C. Sprung,et al. Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012 , 2013, Intensive Care Medicine.
[54] G. Blancho,et al. Myeloid-derived suppressor cells: mechanisms of action and recent advances in their role in transplant tolerance , 2012, Front. Immun..
[55] L. Moldawer,et al. Persistent inflammation and immunosuppression: A common syndrome and new horizon for surgical intensive care , 2012, The journal of trauma and acute care surgery.
[56] H. Wunsch,et al. Population Burden of Long‐Term Survivorship After Severe Sepsis in Older Americans , 2012, Journal of The American Geriatrics Society.
[57] C. Cox. Persistent Systemic Inflammation in Chronic Critical Illness , 2012, Respiratory Care.
[58] C. Alauzet,et al. Myeloid-derived suppressor cells control microbial sepsis , 2012, Intensive Care Medicine.
[59] D. Needham,et al. Improving long-term outcomes after discharge from intensive care unit: Report from a stakeholders' conference* , 2012, Critical care medicine.
[60] Xiaopei Huang,et al. Myeloid-Derived Suppressor Cells Regulate Natural Killer Cell Response to Adenovirus-Mediated Gene Transfer , 2012, Journal of Virology.
[61] Arthur S Slutsky,et al. Ventilator-induced lung injury and sepsis: two sides of the same coin? , 2011, Minerva anestesiologica.
[62] M. J. Hall,et al. Inpatient care for septicemia or sepsis: a challenge for patients and hospitals. , 2011, NCHS data brief.
[63] Lyle L. Moldawer,et al. A Paradoxical Role for Myeloid-Derived Suppressor Cells in Sepsis and Trauma , 2011, Molecular medicine.
[64] K. Langa,et al. Long-term cognitive impairment and functional disability among survivors of severe sepsis. , 2010, JAMA.
[65] R. Hotchkiss,et al. Immunotherapy for sepsis--a new approach against an ancient foe. , 2010, The New England journal of medicine.
[66] J. Vincent,et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. , 2010, Cancer research.
[67] R. Hotchkiss,et al. IL-7 Promotes T Cell Viability, Trafficking, and Functionality and Improves Survival in Sepsis , 2010, The Journal of Immunology.
[68] Javier Llorca,et al. Impact of the Surviving Sepsis Campaign protocols on hospital length of stay and mortality in septic shock patients: Results of a three-year follow-up quasi-experimental study* , 2010, Critical care medicine.
[69] S. Akira,et al. Cutting Edge: Bacterial Infection Induces Hematopoietic Stem and Progenitor Cell Expansion in the Absence of TLR Signaling , 2010, The Journal of Immunology.
[70] Richard Beale,et al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis , 2010, Intensive Care Medicine.
[71] C. Coopersmith,et al. IL-15 Prevents Apoptosis, Reverses Innate and Adaptive Immune Dysfunction, and Improves Survival in Sepsis , 2009, The Journal of Immunology.
[72] V. Bronte. Myeloid‐derived suppressor cells in inflammation: Uncovering cell subsets with enhanced immunosuppressive functions , 2009, European journal of immunology.
[73] A. Kalil,et al. Prevalence and mortality associated with cytomegalovirus infection in nonimmunosuppressed patients in the intensive care unit* , 2009, Critical care medicine.
[74] E. Ruokonen,et al. Long-term outcome and quality-adjusted life years after severe sepsis* , 2009, Critical care medicine.
[75] B. Rini,et al. Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients , 2009, Clinical Cancer Research.
[76] Srinivas Nagaraj,et al. Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.
[77] B. Casserly,et al. The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. , 2008, Clinics in chest medicine.
[78] A. Limaye,et al. Reactivation of Cytomegalovirus Infection in Critically Ill Immunocompetent Patients—Reply , 2008 .
[79] S. Rankin,et al. Neutrophil mobilization and clearance in the bone marrow , 2008, Immunology.
[80] G. Rubenfeld,et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. , 2008, JAMA.
[81] K. Gupta,et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer , 2007, Nature Medicine.
[82] L. Moldawer,et al. MyD88-dependent expansion of an immature GR-1+CD11b+ population induces T cell suppression and Th2 polarization in sepsis , 2007, The Journal of experimental medicine.
[83] Sandy Schwemberger,et al. THERMAL INJURY ELEVATES THE INFLAMMATORY MONOCYTE SUBPOPULATION IN MULTIPLE COMPARTMENTS , 2007, Shock.
[84] H. Zeh,et al. Arginine and immunity. , 2007, The Journal of nutrition.
[85] J. Govert,et al. Differences in one-year health outcomes and resource utilization by definition of prolonged mechanical ventilation: a prospective cohort study , 2007, Critical care.
[86] Ingo Fricke,et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. , 2006, Cancer research.
[87] C. Coopersmith,et al. The systemic inflammatory response syndrome. , 2006, Microbes and infection.
[88] J. Ochoa,et al. CD11b+/Gr-1+ Myeloid Suppressor Cells Cause T Cell Dysfunction after Traumatic Stress1 , 2006, The Journal of Immunology.
[89] F. Gao,et al. The impact of compliance with 6-hour and 24-hour sepsis bundles on hospital mortality in patients with severe sepsis: a prospective observational study , 2005, Critical care.
[90] L. Kaiser,et al. Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity , 2005, Clinical Cancer Research.
[91] V. Bronte,et al. Regulation of immune responses by L-arginine metabolism , 2005, Nature Reviews Immunology.
[92] G. Kelsoe,et al. Inflammation and the reciprocal production of granulocytes and lymphocytes in bone marrow , 2005, The Journal of experimental medicine.
[93] Herwig Gerlach,et al. Reply to Zandstra and van der Voort , 2004, Intensive Care Medicine.
[94] Mitchell M. Levy,et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock , 2004, Critical care medicine.
[95] P. Bach,et al. The epidemiology and costs of chronic critical illness. , 2002, Critical care clinics.
[96] L. Moldawer,et al. Apoptosis in sepsis: a new target for therapeutic exploration , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[97] R. Hotchkiss,et al. Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte , 2000, Nature Immunology.
[98] D. Heyland,et al. Long-term health-related quality of life in survivors of sepsis. Short Form 36: A valid and reliable measure of health-related quality of life , 2000, Critical care medicine.
[99] S. Korsmeyer,et al. Prevention of lymphocyte cell death in sepsis improves survival in mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[100] B. Giroir. Mediators of septic shock: New approaches for interrupting the endogenous inflammatory cascade , 1993, Critical care medicine.
[101] W. Knaus,et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.
[102] D. Remick,et al. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. , 1992, The Journal of clinical investigation.
[103] J. Norton,et al. A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice , 1991, The Journal of experimental medicine.
[104] B. Beutler,et al. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin , 1985, Nature.
[105] Cyrus Chargari,et al. Epstein-Barr virus reactivation in critically ill immunocompetent patients , 2015, Biomedical journal.
[106] C. Divino,et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. , 2010, Cancer research.
[107] Shannon S Carson,et al. Chronic critical illness. , 2010, American journal of respiratory and critical care medicine.
[108] L. Moldawer,et al. MyD 88-dependent expansion of an immature GR-1 + CD 11 b + population induces T cell suppression and Th 2 polarization in sepsis , 2007 .
[109] Gordon S Doig,et al. Post-ICU mechanical ventilation at 23 long-term care hospitals: a multicenter outcomes study. , 2007, Chest.
[110] S. Mocellin,et al. Arginase, Nitric Oxide Synthase, and Novel Inhibitors of L-arginine Metabolism in Immune Modulation , 2007 .